Search by CAS No , Chemical Name or Molecular Formula
"Aflibercept (INN, USAN) is a biopharmaceutical drug invented by Regeneron Pharmaceuticals, approved in the United States and Europe for the treatment of wet macular degeneration under the trade name Eylea, and for metastatic colorectal cancer as Zaltrap. As the active ingredient of Zaltrap, the substance is called ziv-aflibercept in the US.
It is an inhibitor of vascular endothelial growth factor (VEGF).
Aflibercept is being co-developed for cancer treatment by Sanofi and Regeneron under a deal signed in 2003, and is being co-developed for eye diseases by Bayer HealthCare and Regeneron under a deal signed in 2006.",""
It is an inhibitor of vascular endothelial growth factor.
Wiegand SJ (May 2008); Fraser ;HM (July 2008)
We normally respond within 8 hours.
This page contains information about Aflibercept Cas # 862111-32-8 and its API Standards.
Aflibercept Aflibercept Worldwide Suppliers of Aflibercept https://www.clearsynth.com/en/CSO11214.html API Standards Clearsynth 862111-32-8
Product rating: 9 Aflibercept based on 20 ratings
Keywords: API Standards seryl-α-aspartylthreonylglycylarginylprolylphenylalanylvalyl-α-glutamylmethionyltyrosylseryl-α-glutamylisoleucylprolyl-α-glutamylisoleucylisoleucylhistidylmethionylthreonyl-α-glutamylglycylarginyl-α-glutamylleucylvalylisoleucylprolylcysteinylarginylvalylthreonylserylprolylasparagylisoleucylthreonylvalylthreonylleucyllysyllysylphenylalanylprolylleucyl-α-aspartylthreonylleucylisoleucylprolyl-α-aspartylglycyllysylarginylisoleucylisoleucyltryptophyl-α-aspartylserine CS-O-11214 Aflibercept Aflibercept 862111-32-8 6856.9 C308H495N79O91S3
Internal standard, Internal standard Aflibercept, HPLC-MS method validation, HPLC-MS method validation Aflibercept, LC-MS-MS method validation, LC-MS-MS method validation Aflibercept, Deuterated internal standard, Deuterated internal standard Aflibercept, Deuterated Aflibercept, Deuterium labeled Aflibercept, Quantitative bioanalytical methods, Quantitative bioanalytical methods Aflibercept, Blood samples Aflibercept, Blood concentrations, Heavy drugs, Analysis, Analysis Aflibercept, Clinical diagnostic, Clinical diagnostic Aflibercept, Dosing Aflibercept, Analytical method development, Internal standard method.
CLEARSYNTH CANADA INC.
2395 Speakman Drive,
Lab: 1001, Mississauga, ON,
Canada L5K 1B3
T : +1-289-729-0060
CLEARSYNTH RESEARCH CENTRE
Plot No. 177, IDA, Mallapur,
T : +91-40-27155481
CLEARSYNTH LABS LTD
17, Lotus Business Park,
Andheri (W), Mumbai - 400053
T : +91-22-45045945